ALK and non-small cell lung carcinoma: The dual ALK‐cMET inhibitor crizotinib has been approved for the treatment of ALK‐rearranged NSCLC and is currently undergoing trials as a treatment for cMET‐driven NSCLC (Bahcall et al., 2016).